November 18, 2025 · Form 4 insider transaction
Renninger Robert bought 1,000 shares of Athira Pharma, Inc. at $2.31 per share, a transaction worth $2.3K. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 48 days after the transaction.
The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 19, 2025 through November 18, 2025. This transaction is also exempt under Rule 16b-3(c).; The reported number of shares in this Form 4 has been adjusted to reflect the impact of the Issuer's 10-for-1 reverse stock split completed on September 17, 2025 (the "Reverse Stock Split").; The Purchase Period ended November 18, 2025 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 19, 2025.; In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2025.